retatrutide trial update october 2025 Lilly's Scores Triple Triumph With 26% Weight Loss, But New Safety Signal Emerges I personally know plenty of

To view or add a comment, sign in Global Drug Highlights: Innovations Shaping Healthcare Worldwide From targeted cancer therapies and immunotherapies to breakthrough treatments for Type 1 Diabetes and migraine prevention, the pharmaceutical landscape continues to evolve across major global markets

Some patients regain part of the weight after treatment ends because appetite and hunger signals can return

(available at: [Google Scholar] 73.Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson Jet al

Setting realistic expectations is crucial: weight loss is gradual, with clinical trials showing approximately 15% weight reduction with semaglutide 2.4 mg at 68 weeks and up to 21% with tirzepatide at 72 weeks, though individual responses vary considerably

Some are approved for type 2 diabetes